Table 1 Clinical features of patients treated with ICIs.

From: Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

  

Study population (N = 171)

Molecular subset (N = 32)

Age at diagnosis

Median (Q1, Q3)

67 (62, 73.5)

65.5 (60.5, 71)

Sex

0

109 (63.7%)

24 (75.0%)

 

1

62 (36.3%)

8 (25.0%)

Smoking

No

25 (14.6%)

2 (6.2%)

 

Yes

56 (32.7%)

10 (31.2%)

 

Former

90 (52.6%)

20 (62.5%)

Performance status

0

76 (44.4%)

15 (46.9%)

 

1

90 (52.6%)

15 (46.9%)

 

2

5 (2.9%)

2 (6.2%)

Histology

Adenocarcinoma

132 (77.2%)

25 (78.1%)

 

Squamous

26 (15.2%)

6 (18.8%)

 

Other

13 (7.6%)

1 (3.1%)

PD-L1

N-Miss

48

7

 

Negative

40 (32.5%)

15 (60.0%)

 

Positive

83 (67.5%)

10 (40.0%)

PD-L1

N-Miss

48

7

 

<50%

59 (48.0%)

17 (68.0%)

 

≥50%

64 (52.0%)

8 (32.0%)

Extrathoracic sites

0

67 (39.2%)

13 (40.6%)

 

1

50 (29.2%)

8 (25.0%)

 

>1

54 (31.6%)

11 (34.4%)

Number of metastatic sites

0–1

80 (46.8%)

18 (56.2%)

 

2–4

91 (53.2%)

14 (43.8%)

Treatment lines

1

67 (39.2%)

9 (28.1%)

 

>1

104 (60.8%)

23 (71.9%)

  1. Clinical characteristics of patients of the whole treated population with ICIs and of patients considered for molecular evaluation.
Back to article page